Opko Health Divestiture to Laboratory Corporation of America Holdings for $722M
OPKO Health and its subsidiary BioReference Health entered into a definitive agreement to sell certain assets of their clinical and anatomic pathology laboratory testing business to Labcorp for $722 million in cash. The deal includes clinical and women’s health testing, urology, and the proprietary 4Kscore prostate cancer test, with OPKO eligible for up to an additional $150 million in milestone payments over ten years based on 4Kscore revenue. The transaction is subject to HSR Clearance and customary closing conditions, with a target completion date by April 14, 2027.
- Value
- $722M
- Counterparty
- Laboratory Corporation of America Holdings
- Term
- up to 10 years